FOXP3 expression in esophageal squamous cell carcinoma: Implications for cetuximab sensitivity and therapeutic strategies
S Wu, Y Wang, Z Xiao, J Zhang, Z He, M Ye - Wiener klinische …, 2024 - Springer
Objective Investigating the impact of FOXP3 (transcription factor forkhead box P3)
expression on the biological behavior of esophageal squamous cell carcinoma (ESCC) and …
expression on the biological behavior of esophageal squamous cell carcinoma (ESCC) and …
Defucosylated anti-epidermal growth factor receptor monoclonal antibody exerted antitumor activities in mouse xenograft models of canine mammary gland tumor
T Tanaka, T Ohishi, M Saito, H Suzuki… - Monoclonal …, 2022 - liebertpub.com
The epidermal growth factor receptor (EGFR) contributes to tumor malignancy through gene
amplification and/or protein overexpression. In our previous study, we developed an anti …
amplification and/or protein overexpression. In our previous study, we developed an anti …
[HTML][HTML] Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and …
T Nishibata, J Weng, K Omori, Y Sato… - Journal of …, 2024 - Elsevier
The development of targeted cancer therapies based on monoclonal antibodies against
tumor-associated antigens has progressed markedly over recent decades. This approach is …
tumor-associated antigens has progressed markedly over recent decades. This approach is …
[HTML][HTML] Cytokine profiles of head and neck squamous cell carcinoma undergoing dual immunotherapy with cetuximab and pembrolizumab identify interferon gamma …
M Berszin, I Michaelides, J Siemert, L Röhl… - Frontiers in …, 2022 - frontiersin.org
Background: Pembrolizumab and cetuximab are antibodies under investigation in head and
neck squamous cell carcinoma (HNSCC) either as single agents or combined with cisplatin …
neck squamous cell carcinoma (HNSCC) either as single agents or combined with cisplatin …
An investigative meta-analysis on the effectiveness and safety of integrating VEGF/VEGFR inhibitors with PD-1/PD-L1 inhibitors in cases with R/M HNSCC
H Wang, L Hu, F Zhang, M Fang, J Xu, M Li, Z Chen - Oral Oncology, 2024 - Elsevier
Objectives Exploration into the use of vascular endothelial growth factor (VEGF)/VEGF
receptor (VEGFR) inhibitors alongside programmed cell death protein 1 (PD-1)/programmed …
receptor (VEGFR) inhibitors alongside programmed cell death protein 1 (PD-1)/programmed …
[HTML][HTML] The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell …
R Hui, X Liu, Z Fan, H Ji, D Wei, G Ren - Journal of Cancer, 2024 - ncbi.nlm.nih.gov
Purpose: The prognosis of patients with recurrent or metastatic head and neck squamous
cell carcinoma (R/M HNSCC) that are refractory to programmed cell death protein 1 (PD-1) …
cell carcinoma (R/M HNSCC) that are refractory to programmed cell death protein 1 (PD-1) …
Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis
S Zhang, M Zheng, H Tian, W Liu, Z Feng, S Xing… - Oral Oncology, 2024 - Elsevier
Objectives The efficacy of immune checkpoint inhibitors (ICIs) is unclear in patients aged≥
75 years with head and neck squamous cell carcinoma (HNSCC). We conducted a …
75 years with head and neck squamous cell carcinoma (HNSCC). We conducted a …
Anti-VEGF and Anti-EGFR Antibody Therapy on T-Cell Infiltration and TCR Variation in Metastatic Colorectal Cancer
M Xu, R Tsunedomi, K Kiyotani, S Tomochika… - Anticancer …, 2023 - ar.iiarjournals.org
Background/Aim: Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal
antibodies (mAb) is widely used to treat patients with metastatic colorectal cancer (mCRC) …
antibodies (mAb) is widely used to treat patients with metastatic colorectal cancer (mCRC) …
Updates to Treatment of Recurrent Metastatic Head and Neck Cancers
CP Rodriguez - Journal of the National Comprehensive Cancer …, 2024 - jnccn.org
The introduction of immune checkpoint inhibitors (ICIs), such as pembrolizumab and
nivolumab, has significantly improved overall survival in both the first-and second-line …
nivolumab, has significantly improved overall survival in both the first-and second-line …
PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma
DC Mo, JF Huang, PH Luo, L Chen, B Zou… - European Archives of Oto …, 2023 - Springer
Objective This study aimed to evaluate the efficacy and safety of programmed cell death-
1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor plus chemotherapy vs standard of …
1/programmed cell death-ligand 1 (PD-1/PD-L1) inhibitor plus chemotherapy vs standard of …